China Accepts Hansoh Pharmaceutical's Socrodeucitinib Application for Psoriasis Treatment

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • China’s National Medical Products Administration accepted Hansoh Pharmaceutical’s new drug application for socrodeucitinib tablets (HS-10374) for review on November 20, 2026. * The treatment targets adults with moderate-to-severe plaque psoriasis. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261120-12420552), on November 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.